ATE269103T1 - Stabilisierte wässerige glukagonlösungen enthaltend detergenzien - Google Patents

Stabilisierte wässerige glukagonlösungen enthaltend detergenzien

Info

Publication number: ATE269103T1
Authority: AT; Austria
Prior art keywords: solutions containing; stabilized aqueous; containing detergents; glucagon solutions; aqueous glucagon
Prior art date: 1998-03-13

Application number

AT99906095T

Other languages

English (en)

Inventor

Niels C Kaarsholm

Original Assignee

Novo Nordisk As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-13

Filing date

1999-03-08

Publication date

2004-07-15

1999-03-08 Application filed by Novo Nordisk As filed Critical Novo Nordisk As

1999-03-08 Priority claimed from PCT/DK1999/000115 external-priority patent/WO1999047160A1/en

2004-07-15 Application granted granted Critical

2004-07-15 Publication of ATE269103T1 publication Critical patent/ATE269103T1/de

Links

239000003599 detergent Substances 0.000 title abstract 3
102000051325 Glucagon Human genes 0.000 title abstract 2
108060003199 Glucagon Proteins 0.000 title abstract 2
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title abstract 2
229960004666 glucagon Drugs 0.000 title abstract 2
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
102100040918 Pro-glucagon Human genes 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
108090000765 processed proteins & peptides Proteins 0.000 abstract 1
230000003381 solubilizing effect Effects 0.000 abstract 1
230000000087 stabilizing effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Obesity (AREA)
Oil, Petroleum & Natural Gas (AREA)
Hematology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Detergent Compositions (AREA)
Cosmetics (AREA)

AT99906095T 1998-03-13 1999-03-08 Stabilisierte wässerige glukagonlösungen enthaltend detergenzien ATE269103T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98610006		1998-03-13
PCT/DK1999/000115 WO1999047160A1 (en)	1998-03-13	1999-03-08	Stabilized aqueous peptide solutions

Publications (1)

Publication Number	Publication Date
ATE269103T1 true ATE269103T1 (de)	2004-07-15

Family

ID=32524325

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99906095T ATE269103T1 (de)	1998-03-13	1999-03-08	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien

Country Status (3)

Country	Link
US (1)	US6384016B1 (de)
AT (1)	ATE269103T1 (de)
DE (1)	DE69918070T2 (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2003522099A (ja) *	1998-02-27	2003-07-22	ノボノルディスクアクティーゼルスカブ	遅延作用プロファイルを有するｇｌｐ−１のｇｌｐ−１誘導体及びエキセンジン
US6528486B1 (en)	1999-07-12	2003-03-04	Zealand Pharma A/S	Peptide agonists of GLP-1 activity
MXPA02007231A (es) *	2000-01-27	2002-12-09	Lilly Co Eli	Proceso para solubilizar los compuestos de peptido 1 similares a glucagon.
US20020061838A1 (en) *	2000-05-17	2002-05-23	Barton Holmquist	Peptide pharmaceutical formulations
WO2003002136A2 (en) *	2001-06-28	2003-01-09	Novo Nordisk A/S	Stable formulation of modified glp-1
WO2004005342A1 (en)	2002-07-04	2004-01-15	Zealand Pharma A/S	Glp-1 and methods for treating diabetes
BR0314996A (pt) *	2002-10-02	2005-08-09	Zealand Pharma As	Composição, composição farmaceuticamente aceitável, método para produzir a composição, métodos para estabilizar a exendina-4 (1-39) ou uma sua variante, derivado ou análogo contra a degradação, antes, durante ou após o uso pretendido, para tratar doenças, para tratar de estados de doenças associados com nìveis elevados de glicose do sangue, para a regulação dos nìveis de glicose do sangue, para a regulação do esvaziamento gástrico, para estimular a liberação de insulina em um mamìfero para reduzir o nìvel de glicose do sangue em um mamìfero, para reduzir o nìvel de lipìdeos plasmáticos em um mamìfero, para reduzir a mortalidade e a morbidez após o infarto miocárdico em um mamìfero, para estimular a liberação de insulina em um mamìfero, e para produzir uma exendina (1-39) estabilizada, e, exendina (1-39) estabilizada
KR101308912B1 (ko) *	2003-06-03	2013-09-23	노보 노르디스크 에이/에스	안정화된 약학적 펩티드 조성물
PL1633391T3 (pl) *	2003-06-03	2012-03-30	Novo Nordisk As	Stabilizowane farmaceutycznie kompozycje peptydowe
DK3300721T4 (da) *	2003-11-20	2025-03-03	Novo Nordisk As	Propylenglycol-holdige peptidformuleringer hvilke er optimale til fremstilling og til anvendelse i injektionsindretninger
PL1789434T3 (pl) *	2004-08-31	2014-07-31	Novo Nordisk As	Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek
MX2007005521A (es) *	2004-11-12	2007-05-18	Novo Nordisk As	Formulaciones estables de peptidos insulinotropicos.
US20080207490A1 (en) *	2005-07-07	2008-08-28	Postech Foundation	Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications
RS59913B1 (sr)	2008-10-17	2020-03-31	Sanofi Aventis Deutschland	Kombinacija insulina i glp-1-agonista
CN102596175A (zh)	2009-07-06	2012-07-18	赛诺菲-安万特德国有限公司	含有甲硫氨酸的水性胰岛素制备物
US20110097386A1 (en) *	2009-10-22	2011-04-28	Biodel, Inc.	Stabilized glucagon solutions
US9610329B2 (en) *	2009-10-22	2017-04-04	Albireo Pharma, Inc.	Stabilized glucagon solutions
MY180661A (en)	2009-11-13	2020-12-04	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
PT3345593T (pt)	2009-11-13	2023-11-27	Sanofi Aventis Deutschland	Composição farmacêutica compreendendo despro36exendina- 4(1-39)-lys6-nh2 e metionina
WO2011123943A1 (en)	2010-04-09	2011-10-13	Mount Sinai Hospital	Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
CN107129538B (zh)	2010-04-27	2021-07-16	西兰制药公司	Glp-1受体激动剂和胃泌素的肽缀合物及其用途
WO2011138802A1 (en) *	2010-05-07	2011-11-10	Sun Pharma Advanced Research Company Ltd.,	Injection solution
PL2611458T3 (pl)	2010-08-30	2017-02-28	Sanofi-Aventis Deutschland Gmbh	Zastosowanie AVE0010 do produkcji leku do leczenia cukrzycy typu 2
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es)	2011-08-29	2014-04-09	Sanofi Aventis Deutschland	Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TW201326194A (zh)	2011-11-03	2013-07-01	Zealand Pharma As	Ｇｌｐ－１胃泌素受體促效劑肽結合物
US9198971B2 (en)	2012-01-09	2015-12-01	Adocia	Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
IN2015DN00544A (de)	2012-07-23	2015-06-26	Zealand Pharma As
US20150314003A2 (en)	2012-08-09	2015-11-05	Adocia	Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
TWI608013B (zh)	2012-09-17	2017-12-11	西蘭製藥公司	升糖素類似物
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US9988429B2 (en)	2013-10-17	2018-06-05	Zealand Pharma A/S	Glucagon analogues
PL3057984T3 (pl)	2013-10-17	2018-12-31	Zealand Pharma A/S	Acylowane analogi glukagonu
WO2015067715A2 (en)	2013-11-06	2015-05-14	Zealand Pharma A/S	Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh)	2013-11-06	2021-03-12	西兰制药公司	胰高血糖素-glp-1-gip三重激动剂化合物
MX2016008978A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016008979A (es)	2014-01-09	2016-10-04	Sanofi Sa	Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
BR112016015851A2 (pt)	2014-01-09	2017-08-08	Sanofi Sa	Formulações farmacêuticas estabilizadas de insulina aspart
ES2685987T3 (es)	2014-09-05	2018-10-15	University Of Copenhagen	Análogos de péptidos gip
KR102620911B1 (ko)	2014-10-29	2024-01-05	질랜드 파마 에이/에스	Gip 효능제 화합물 및 방법
EP3229828B1 (de)	2014-12-12	2023-04-05	Sanofi-Aventis Deutschland GmbH	Insulin-glargin/lixisenatid-fixierte verhältnisformulierung
DK3244878T3 (da)	2015-01-12	2022-10-17	Enteris Biopharma Inc	Faste orale sammensætningsformer
BR112017014994B1 (pt)	2015-02-17	2023-12-19	Eli Lilly And Company	Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
DK3283507T3 (da)	2015-04-16	2020-01-02	Zealand Pharma As	Acyleret glucagonanalog
BR112018075250A2 (pt)	2016-06-07	2019-03-12	Adocia	composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
EP3551651B1 (de)	2016-12-09	2024-03-06	Zealand Pharma A/S	Acylierte glp-1/glp-2 duale agoniste
KR102743887B1 (ko)	2017-05-31	2024-12-19	유니버시티 오브 코펜하겐	장기-작용성 gip 펩타이드 유사체
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
KR20240171195A (ko)	2017-12-07	2024-12-06	아도시아	인간 글루카곤 및 코-폴리아미노산을 포함하는 주사용 수용액 형태의 조성물
AU2018380993A1 (en)	2017-12-07	2020-06-11	Adocia	Compositions in the form of an injectable aqueous solution comprising human glucagon and a copolyamino acid
US10987426B2 (en)	2017-12-07	2021-04-27	Adocia	Compositions in the form of an injectable aqueous solution comprising human glucagon and a co-polyamino acid
FR3083087A1 (fr)	2018-06-29	2020-01-03	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
US20190275110A1 (en)	2017-12-07	2019-09-12	Adocia	Compositions in the form of an injectale aqueous solution comprising human glucagon and a co-polyamino acid
FR3067247A1 (fr)	2018-06-07	2018-12-14	Adocia	Compositions sous forme d'une solution aqueuse injectable comprenant du glucagon humain et un co-polyaminoacide
SG11202105586YA (en)	2018-12-03	2021-06-29	Antag Therapeutics Aps	Modified gip peptide analogues
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1202607A (en) *	1968-01-10	1970-08-19	Novo Terapeutisk Labor As	Improvements in or relating to stable glucagon solutions and their preparation
US5120712A (en)	1986-05-05	1992-06-09	The General Hospital Corporation	Insulinotropic hormone
HU225496B1 (en)	1993-04-07	2007-01-29	Scios Inc	Pharmaceutical compositions of prolonged delivery, containing peptides
US5652216A (en) *	1994-05-26	1997-07-29	Novo Nordisk A/S	Pharmaceutical preparation
US5707641A (en) *	1994-10-13	1998-01-13	Pharmaderm Research & Development Ltd.	Formulations comprising therapeutically-active proteins or polypeptides

1999
- 1999-03-08 US US09/265,141 patent/US6384016B1/en not_active Expired - Fee Related
- 1999-03-08 DE DE69918070T patent/DE69918070T2/de not_active Expired - Fee Related
- 1999-03-08 AT AT99906095T patent/ATE269103T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6384016B1 (en)	2002-05-07
DE69918070D1 (de)	2004-07-22
DE69918070T2 (de)	2005-08-25

Legal Events

Date	Code	Title	Description
2004-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69918070D1 (de)	2004-07-22	Stabilisierte wässerige glukagonlösungen enthaltend detergenzien
RU97118224A (ru)	1999-07-27	Соединения и композиции для доставки активных агентов
HUP9904596A1 (hu)	2000-06-28	Mellékpajzsmirigy-hormon analógok
FI956310L (fi)	1995-12-28	Stabiloidut farmaseuttiset peptidikoostumukset
DE69736791D1 (de)	2006-11-16	Architecture de programmation d'un circuit avec memoire rom et memoire flash
NO995568D0 (no)	1999-11-12	Paratyroidhormon peptidanaloger
MY126897A (en)	2006-10-31	Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x
ES2052488T1 (es)	1994-07-16	Peptidos antagonistas de la hormona liberadora de hormona luteinizante.
DK0440885T3 (da)	1994-08-08	Blandinger af forbindelser isoleret fra Curcuma Spp. som antiinflammatoriske midler
DE69911993D1 (de)	2003-11-13	Polyol/öl-suspensionen zur verzörgerten freisetzung von proteinen
IT1240314B (it)	1993-12-07	Formulazioni acquose stabilizzate di piccoli peptidi.
PL348048A1 (en)	2002-05-06	Liquid cleaning agent or detergent composition
DE69300873D1 (de)	1996-01-11	Waschmittelzusammensetzungen.
ATE214698T1 (de)	2002-04-15	Neue carbamazepin hapten analoge
PH31076A (en)	1998-02-05	Surfactant blends for detergent compositions.
EP0607103A3 (de)	1997-07-09	Chelatbildende Gruppen enthaltende Somatostatinanaloge und deren radiomarkierten Zusammensetzungen.
BR9407124A (pt)	1996-09-10	Composições contendo surfactante
BR9816029A (pt)	2001-05-29	Composições detergente
AR023006A1 (es)	2002-09-04	Composicion de champu
ATE245028T1 (de)	2003-08-15	Trimegestone enthaltende pharmazeutische zusammensetzungen
DE69208492D1 (de)	1996-04-04	Stabilisierte Polyacetalzusammensetzungen
EP0616800A3 (de)	1995-02-15	Rieckstoffmittel mit verlängerter Diffusion.
NO913919D0 (no)	1991-10-04	Vandig, tiksotropisk vaskemiddelblanding.
MA24608A1 (fr)	1999-04-01	Compositions contenant un sensibilisant a l'insuline, un secretagogue d'insuline et un agent anti-heperglycemique inhibiteur d'alphat-glugosidase.
NL194506B (nl)	2002-02-01	Samenstelling, bevattende een elastomeer en een stabilisatormengsel.